Previously, we have developed N-(3-ethynyl-2, 4-difluorophenyl) sulfonamide derivatives as selective BRAF inhibitors with potent activities against BRAF-mutant CRC cells, and also reported BRAF/epidermal growth factor receptor (EGFR) dual inhibitors for the treatment of drug-resistant CRCs (Cheng et al., 2014; Li et al., 2015; Li et al., 2016). Here, BRAF is linked to colorectal carcinoma.